Co-Author
This page shows the publications co-authored by Robert Haddad and Danielle Margalit.
Connection Strength
2.725
-
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
Score: 0.241
-
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
Score: 0.224
-
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
Score: 0.207
-
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
Score: 0.204
-
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
Score: 0.192
-
Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
Score: 0.181
-
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
Score: 0.181
-
Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
Score: 0.168
-
Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
Score: 0.165
-
Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
Score: 0.151
-
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 Mar 31.
Score: 0.062
-
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
Score: 0.061
-
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
Score: 0.056
-
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
Score: 0.056
-
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
Score: 0.056
-
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
Score: 0.054
-
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
Score: 0.054
-
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
Score: 0.054
-
Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
Score: 0.050
-
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
Score: 0.050
-
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
Score: 0.046
-
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
Score: 0.044
-
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
Score: 0.043
-
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
Score: 0.042
-
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
Score: 0.042
-
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.